Patrick J. McEnany 
Co-Founder, Chairman, President and Chief Executive Officer

Patrick J. McEnany has been Chief Executive Officer and a director of Catalyst since its formation in January 2002. In 2006 he became Chairman, President and Chief Executive Officer. From 1991 to April of 1997, Mr. McEnany was Chairman and Chief Executive Officer of Royce Laboratories, Inc. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as President of the wholly-owned Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals, Inc. From 1993 through 1997, he also served as Vice Chairman and Director of the National Association of Pharmaceutical Manufacturers. He currently serves on the Board of Directors for the Jackson Memorial Hospital Foundation.

Steven R. Miller
Chief Operating Officer and Chief Scientific Officer

Steven R. Miller, PhD, is responsible for Catalyst’s product development program, which includes all aspects of chemistry and manufacturing controls, quality systems, contract operations, and development planning. Dr. Miller has 25 years of experience in the pharmaceutical and healthcare industries, joining Catalyst in 2007. Most recently he has managed Catalyst’s in-licensing of CPP-115 and Catalyst’s newest drug, Firdapse®, and taken these products through various preclinical and clinical development studies. Dr. Miller previously served as Executive Director for Research and Development Operations at Watson Pharmaceuticals and as Vice President of Research and Product Development at Royce Laboratories; he has also managed medical device development groups at Baxter Diagnostics and worked as an analytical chemist for the U.S. Food and Drug Administration. Dr. Miller received his doctorate in physical organic chemistry at the University of Miami; his work has been published in numerous technical and professional journals including Journal of Analytical Chemistry, Journal of the American Chemical Society, Journal of Medicinal Chemistry, and Chemical Communications.

Alicia Grande
Vice President, Chief Financial Officer and Treasurer

Alicia Grande, CPA, CMA, was appointed Vice President, Chief Financial Officer and Treasurer of Catalyst in December 2011, having joined the company as Corporate Controller and Chief Accounting Officer in 2007. Prior to that, she was Senior Director of Finance for The Hackett Group, Inc. (then known as Answerthink, Inc.), where she was responsible for all external and SEC financial reporting and served as head of the firm’s Sarbanes-Oxley Act compliance team. Ms. Grande previously was employed for more than 10 years by various public accounting firms, including Arthur Andersen, LLP. Ms. Grande earned a bachelor of science degree in business administration, with majors in accounting and finance, from Syracuse University and a master of accounting degree from Florida International University.

Gary Ingenito
Chief Medical Officer

Gary Ingenito, MD, PhD, joined Catalyst in July 2015 as Chief Medical Officer. Dr. Ingenito brings more than 25 years of knowledge and experience in the field of pharmaceutical development: including drugs, biologics, and combination products. During this time, Dr. Ingenito held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr. Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr. Ingenito has held positions at Corning-Besselaar, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and Boehringer-Ingelheim Pharmaceuticals. After obtaining his bachelor of arts degree from Johns Hopkins University, Dr. Ingenito earned his medical degree at Jefferson Medical College, and a doctor of philosophy degree from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital.

Brian Elsbernd
Senior Vice President, Legal and Compliance

Brian Elsbernd joined Catalyst in February 2016 as the Senior Vice President of Legal and Compliance. Prior to joining Catalyst, Mr. Elsbernd was Senior Director of US Healthcare Compliance at Mallinckrodt Pharmaceuticals, a growing US specialty pharmaceutical business. From its inception, he led their healthcare compliance and business ethics program while also managing multiple other legal and business functions. Previously, Mr. Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing healthcare providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr. Elsbernd earned his law degree from Saint Louis University School of Law and his undergraduate degree at the University of Illinois.

David J. Caponera
Vice President, Patient Engagement and Access Support

David J. Caponera joined us in October 2014 as our Vice President, Patient Engagement and Access Support. Mr. Caponera has more than 30 years of successful healthcare experience ranging from clinical development, managing payer operations and extensive orphan drug product launches, and implementing reimbursement and patient advocacy programs, with the last 15 years focused on rare diseases and orphan products. From December 2013 until he joined us, Mr. Caponera was an independent consultant to the orphan drug industry. Prior thereto, from January 2011 until October 2013, Mr. Caponera served as Vice President, Patient Advocacy and Reimbursement for Aegerion Pharmaceuticals, Inc., where he established and built its patient advocacy and patient assistance organizations for the launch of Juxtapid™, the company’s first ultra-rare disease product. Prior to that, from November 2009 until January 2011, Mr. Caponera was the Director, Access Services for Pfizer, Inc., where he developed a global patient access network for the launch of ELELYSO™ for ultra-rare Gaucher disease. Prior thereto, Mr. Caponera served as Senior Director of Reimbursement and Distribution for Amicus Therapeutics, Inc., Vice President, Strategic Initiatives for Theracom, Inc., and Senior Director, Patient and Product Services for Genzyme Corporation. At Genzyme he led the case management functions for multiple orphan products, developed the reimbursement and patient management programs for two new product launches, and directed the customer services functions. In addition, Mr. Caponera has held positions at Blue Cross Blue Shield of Massachusetts, including Product Manager for Managed Care and Harvard Community Health Plan (now Harvard Pilgrim Health Care). Mr. Caponera holds a bachelor’s degree in biology from Cornell University and a master’s degree in health administration from Duke University.